An update on the pharmacological management of adenomyosis

Review OA: closed CC-BY-4.0 ⤵ 1 in-corpus citation
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-11 ⓘ

This review explores pharmacological management of adenomyosis, finding limited high-quality clinical trials but identifying therapeutic targets from in vitro and animal studies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-11-04 · read from full text ⓘ

This review article evaluates current pharmacological strategies for treating adenomyosis, focusing on hormonal therapies such as progestins, combined oral contraceptives, and gonadotropin-releasing hormone agonists. The authors analyze the efficacy of these treatments in reducing pain and menstrual bleeding while noting that medical management typically provides symptomatic relief rather than a cure. A significant limitation highlighted is the lack of large-scale randomized controlled trials to establish definitive treatment protocols or long-term outcomes. This paper is centrally about adenomyosis — specifically reviewing the effectiveness and limitations of various drug-based interventions for managing its symptoms.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

INTRODUCTION: Adenomyosis, characterized by the infiltration of the myometrium by ectopic endometrial islets, is a common condition that causes dysmenorrhea, abnormal uterine bleeding and infertility. Different treatment options exist, including medical and surgical treatments. The most commonly used medications are NSAIDs, progestogens and GnRH agonists (GnRHas). AREAS COVERED: We conducted a literature search for in vitro and animal studies, randomized and non-randomized studies, systematic reviews and ongoing trials registered on ClinicalTrials.gov. There are almost no well-conducted randomized controlled trials on the pharmacological treatment of adenomyosis and the information collected from published studies is insufficient. Several therapeutic targets have been identified through animal and in vitro studies, and it is hoped that they will lead to further clinical studies on new compounds and treatment targets in this heterogeneous disease. EXPERT OPINION: Hysterectomy is very effective at treating women with symptomatic adenomyosis who have completed their wish of pregnancy. For women with a future desire of pregnancy medical treatments remain the best options. Progestogens and GnRHas are the most frequently used long-term treatments for abnormal uterine bleeding and pain symptoms. In assisted reproductive techniques long agonist stimulation protocols and pretreatment with GnRHas for differed embryo transfer seem to improve pregnancy rates.
Full text 561 characters · extracted from oa-html · click to expand
An update on the pharmacological management of adenomyosis Published inExpert opinion on pharmacotherapy, vol. 15, no. 16, p. 2347-2360 Publication date2014 UNIGE affiliation entities UNIGE research groups Citation (ISO format) STREULI, Marie Isabelle et al. An update on the pharmacological management of adenomyosis. In: Expert opinion on pharmacotherapy, 2014, vol. 15, n° 16, p. 2347–2360. doi: 10.1517/14656566.2014.953055 Main files (1) Article (Published version) Identifiers - PID : unige:77291 - DOI : 10.1517/14656566.2014.953055 Journal ISSN1465-6566

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

chronic_pelvic_painadenomyosisdysmenorrheainfertility

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Angiogenesis Inhibitors Angiogenesis Inhibitors Angiogenesis Inhibitors Animals Animals Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents, Non-Steroidal Clinical Trials as Topic Clinical Trials as Topic Female Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

europepmc
last seen: 2026-11-21T06:17:04.340742+00:00
pubmed
last seen: 2026-10-08T21:14:18.823929+00:00
unpaywall
last seen: 2026-10-28T06:33:34.531809+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine